Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide + bevacizumab in recurrent glioblastoma (phase II, single-arm)
ChiCTR2600115949Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teniposide and bevacizumab in glioblastoma (GBM), sponsored by Henan Cancer Hospital. Primary endpoints: Objective Response Rate, Disease Control Rate and 3 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
teniposidebevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2600115949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115949.